Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Pitching Frazier Life Sciences? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room